These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

293 related items for PubMed ID: 26063503

  • 21. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies.
    Angiolillo DJ, Gibson CM, Cheng S, Ollier C, Nicolas O, Bergougnan L, Perrin L, LaCreta FP, Hurbin F, Dubar M.
    Clin Pharmacol Ther; 2011 Jan; 89(1):65-74. PubMed ID: 20844485
    [Abstract] [Full Text] [Related]

  • 22. The effect of CYP2C19 genotype on the time course of platelet aggregation inhibition after clopidogrel administration.
    Kim HS, Cho DY, Park BM, Bae SK, Yoon YJ, Oh M, Ghim JL, Kim EY, Kim DH, Shin JG.
    J Clin Pharmacol; 2014 Aug; 54(8):850-7. PubMed ID: 24214141
    [Abstract] [Full Text] [Related]

  • 23. The Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Japanese Volunteers.
    Umemura K, Iwaki T.
    Clin Pharmacol Drug Dev; 2016 Nov; 5(6):480-487. PubMed ID: 27514617
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Effects of CYP2C19 Genetic Polymorphisms on the Pharmacokinetic and Pharmacodynamic Properties of Clopidogrel and Its Active Metabolite in Healthy Chinese Subjects.
    Song BL, Wan M, Tang D, Sun C, Zhu YB, Linda N, Fan HW, Zou JJ.
    Clin Ther; 2018 Jul; 40(7):1170-1178. PubMed ID: 30017169
    [Abstract] [Full Text] [Related]

  • 26. Prediction of clopidogrel low responders by a rapid CYP2C19 activity test.
    Tazaki J, Jinnai T, Tada T, Kato Y, Makiyama T, Ikeda T, Yamane K, Naruse Y, Takahashi K, Watanabe H, Kimura T, Horiuchi H.
    J Atheroscler Thromb; 2012 Jul; 19(2):186-93. PubMed ID: 22166969
    [Abstract] [Full Text] [Related]

  • 27. Platelet reactivity in the early and late phases of acute coronary syndromes according to cytochrome P450 2C19 phenotypes.
    Nagashima Z, Tsukahara K, Morita S, Endo T, Sugano T, Hibi K, Himeno H, Fukui K, Umemura S, Kimura K.
    J Cardiol; 2013 Sep; 62(3):158-64. PubMed ID: 23886632
    [Abstract] [Full Text] [Related]

  • 28. Evaluation of CYP2C19, P2Y12, and ABCB1 polymorphisms and phenotypic response to clopidogrel in healthy Indian adults.
    Sridharan K, Kataria R, Tolani D, Bendkhale S, Gogtay NJ, Thatte UM.
    Indian J Pharmacol; 2016 Sep; 48(4):350-354. PubMed ID: 27756942
    [Abstract] [Full Text] [Related]

  • 29. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in Japanese patients with stable coronary artery disease.
    Nishi T, Ariyoshi N, Nakayama T, Fujimoto Y, Sugimoto K, Takahara M, Wakabayashi S, Koshizaka M, Hanaoka H, Kobayashi Y.
    Circ J; 2015 Sep; 79(11):2439-44. PubMed ID: 26310876
    [Abstract] [Full Text] [Related]

  • 30. Impact of CYP3A5 polymorphism on platelet reactivity at percutaneous coronary intervention and after 9 months of aspirin and clopidogrel therapy in Japanese patients with coronary artery disease.
    Hokimoto S, Chitose T, Mizobe M, Akasaka T, Arima Y, Kaikita K, Iwashita S, Morita K, Miyazaki H, Oniki K, Matsui K, Nakagawa K, Ogawa H.
    Eur J Clin Pharmacol; 2014 Jun; 70(6):667-73. PubMed ID: 24763934
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
    Frelinger AL, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, Brooks JK, Bhatt DL, Michelson AD.
    J Am Coll Cardiol; 2012 Apr 03; 59(14):1304-11. PubMed ID: 22464259
    [Abstract] [Full Text] [Related]

  • 38. Physiologically based pharmacokinetic modeling for sequential metabolism: effect of CYP2C19 genetic polymorphism on clopidogrel and clopidogrel active metabolite pharmacokinetics.
    Djebli N, Fabre D, Boulenc X, Fabre G, Sultan E, Hurbin F.
    Drug Metab Dispos; 2015 Apr 03; 43(4):510-22. PubMed ID: 25609219
    [Abstract] [Full Text] [Related]

  • 39. Impact of CYP2C19 polymorphisms on the antiplatelet effect of clopidogrel in an actual clinical setting in Japan.
    Jinnai T, Horiuchi H, Makiyama T, Tazaki J, Tada T, Akao M, Ono K, Hoshino K, Naruse Y, Takahashi K, Watanabe H, Kita T, Kimura T.
    Circ J; 2009 Aug 03; 73(8):1498-503. PubMed ID: 19531897
    [Abstract] [Full Text] [Related]

  • 40. Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response.
    Gong IY, Crown N, Suen CM, Schwarz UI, Dresser GK, Knauer MJ, Sugiyama D, DeGorter MK, Woolsey S, Tirona RG, Kim RB.
    Eur Heart J; 2012 Nov 03; 33(22):2856-2464a. PubMed ID: 22374717
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.